BioSpace News Archive

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.

Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results for the first quarter of 2021 and provided business updates.

Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement

Castellum, Inc. announces record revenue for the quarter ended March 31, 2021 and its fifth consecutive quarter of positive adjusted EBITDA.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA to decrease the appearance of glabellar lines, also known as frown lines between the eyes.

microCETI™ supports all laser processes in microLED display manufacturing with up to several orders of magnitude higher transfer rates; multiple system orders already received

Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, announced today the appointment of Eric Carter, M.D., Ph.D., to the Board of Directors (BOD), and the hiring of Simon Daggett as Vice President, Clinical Operations and Project Management.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced it will be featured as a presenting company at the following investor conferences: Benzinga Global SmallCap Conference on May 13, 2021

Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases